

NMS Labs

200 Welsh Road, Horsham, PA 19044-2208 Phone: (215) 657-4900 Fax: (215) 657-2972 e-mail: nms@nmslabs.com Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report Report Issued 03/30/2020 14:11 Last Report Issued 03/14/2019 10:47 88888 Clinical Example Report Attn: Example Reports 200 Welsh Road Horsham, PA 19044		Given DOB Not C lot Given e r 06011931	
Sample ID 06011931-001 Matrix Serum or Plasma Patient Name 8689SP-POS Patient ID 8689SP-POS Container Type Clear vial Receipt Notes None Entered	Source N	t/Tm Not Given lot Given ol/Weight Not Given	
Analysis and Comments	Result	Units	Reporting Limit Notes
8689SP Thioridazine and Metabolite, Serum/Plasma Analysis by Gas Chromatography (GC) and Gas Chromatography/Mass Spectrometry (GC/MS)			
Thioridazine Synonym(s): Mellaril® Steady-state serum concentration during chronic oral administration of 400 mg daily: 140 - 2600 ng/mL. Therapeutic steady-state concentrations may overlap levels associated with toxicity.	10000	ng/mL	100 ELEVATED
Mesoridazine	10000	ng/mL	100

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.